Cargando…

Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values

Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Melhem, Marcia S. C., Coelho, Vivian C., Fonseca, Claudia A., de Oliveira, Lidiane, Bonfietti, Lucas X., Szeszs, Maria. W., Magri, Marcello M. C., Dorneles, Francine S., Taguchi, Hideaki, Moreira, Daniel V. S., Motta, Adriana L., Batista, Marjorie V., Kamei, Katsuhiko, Shikanai-Yasuda, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607534/
https://www.ncbi.nlm.nih.gov/pubmed/36297597
http://dx.doi.org/10.3390/pharmaceutics14102161
_version_ 1784818569160163328
author Melhem, Marcia S. C.
Coelho, Vivian C.
Fonseca, Claudia A.
de Oliveira, Lidiane
Bonfietti, Lucas X.
Szeszs, Maria. W.
Magri, Marcello M. C.
Dorneles, Francine S.
Taguchi, Hideaki
Moreira, Daniel V. S.
Motta, Adriana L.
Batista, Marjorie V.
Kamei, Katsuhiko
Shikanai-Yasuda, Maria A.
author_facet Melhem, Marcia S. C.
Coelho, Vivian C.
Fonseca, Claudia A.
de Oliveira, Lidiane
Bonfietti, Lucas X.
Szeszs, Maria. W.
Magri, Marcello M. C.
Dorneles, Francine S.
Taguchi, Hideaki
Moreira, Daniel V. S.
Motta, Adriana L.
Batista, Marjorie V.
Kamei, Katsuhiko
Shikanai-Yasuda, Maria A.
author_sort Melhem, Marcia S. C.
collection PubMed
description Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference methodologies. The Sensititre YeastOne (SYO) and Etest methods are widely utilized for yeasts but have not been extensively evaluated for Aspergillus isolates. We obtained Posaconazole (POS), Voriconazole (VCZ), Itraconazole (ITC), Amphotericin B (AMB), Caspofungin (CAS), and Anidulafungin (AND) minimum inhibitory concentrations (MICs) for both the Etest (n = 330) and SYO (n = 339) methods for 106 sequenced clinical strains. For 84 A. fumigatus, we analyzed the performance of both commercial methods in comparison with the CLSI-AFST, using available cutoff values. An excellent correlation could be demonstrated for Etest-AMB and Etest-VCZ (p < 0.01). SYO-MICs of AMB, VCZ, and POS resulted in excellent essential agreement (>93%), and >80% for AMB, VCZ, and ITC Etest-MICs. High categoric agreement was found for AMB, ITC, and CAS Etest-MICs (>85%) and AMB SYO-MICs (>90%). The considerable number of major/very major errors found using Etest and SYO, possibly related to the proposed cutoffs and associated with the less time-consuming processes, support the need for the improvement of commercial methods for Aspergillus strains.
format Online
Article
Text
id pubmed-9607534
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96075342022-10-28 Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values Melhem, Marcia S. C. Coelho, Vivian C. Fonseca, Claudia A. de Oliveira, Lidiane Bonfietti, Lucas X. Szeszs, Maria. W. Magri, Marcello M. C. Dorneles, Francine S. Taguchi, Hideaki Moreira, Daniel V. S. Motta, Adriana L. Batista, Marjorie V. Kamei, Katsuhiko Shikanai-Yasuda, Maria A. Pharmaceutics Article Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference methodologies. The Sensititre YeastOne (SYO) and Etest methods are widely utilized for yeasts but have not been extensively evaluated for Aspergillus isolates. We obtained Posaconazole (POS), Voriconazole (VCZ), Itraconazole (ITC), Amphotericin B (AMB), Caspofungin (CAS), and Anidulafungin (AND) minimum inhibitory concentrations (MICs) for both the Etest (n = 330) and SYO (n = 339) methods for 106 sequenced clinical strains. For 84 A. fumigatus, we analyzed the performance of both commercial methods in comparison with the CLSI-AFST, using available cutoff values. An excellent correlation could be demonstrated for Etest-AMB and Etest-VCZ (p < 0.01). SYO-MICs of AMB, VCZ, and POS resulted in excellent essential agreement (>93%), and >80% for AMB, VCZ, and ITC Etest-MICs. High categoric agreement was found for AMB, ITC, and CAS Etest-MICs (>85%) and AMB SYO-MICs (>90%). The considerable number of major/very major errors found using Etest and SYO, possibly related to the proposed cutoffs and associated with the less time-consuming processes, support the need for the improvement of commercial methods for Aspergillus strains. MDPI 2022-10-11 /pmc/articles/PMC9607534/ /pubmed/36297597 http://dx.doi.org/10.3390/pharmaceutics14102161 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Melhem, Marcia S. C.
Coelho, Vivian C.
Fonseca, Claudia A.
de Oliveira, Lidiane
Bonfietti, Lucas X.
Szeszs, Maria. W.
Magri, Marcello M. C.
Dorneles, Francine S.
Taguchi, Hideaki
Moreira, Daniel V. S.
Motta, Adriana L.
Batista, Marjorie V.
Kamei, Katsuhiko
Shikanai-Yasuda, Maria A.
Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
title Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
title_full Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
title_fullStr Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
title_full_unstemmed Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
title_short Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
title_sort evaluation of the sensititre yeastone and etest in comparison with clsi m38-a2 for antifungal susceptibility testing of three azoles, amphotericin b, caspofungin, and anidulafungin, against aspergillus fumigatus and other species, using new clinical breakpoints and epidemiological cutoff values
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607534/
https://www.ncbi.nlm.nih.gov/pubmed/36297597
http://dx.doi.org/10.3390/pharmaceutics14102161
work_keys_str_mv AT melhemmarciasc evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT coelhovivianc evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT fonsecaclaudiaa evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT deoliveiralidiane evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT bonfiettilucasx evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT szeszsmariaw evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT magrimarcellomc evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT dornelesfrancines evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT taguchihideaki evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT moreiradanielvs evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT mottaadrianal evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT batistamarjoriev evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT kameikatsuhiko evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues
AT shikanaiyasudamariaa evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues